An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Abstract #1697

Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.
Aim(s): This is an open-label, single-arm study to further assess the efficacy and safety of sulfatinib in pts with advanced grade 1 or 2 NETs.
Materials and methods: Sulfatinib was orally given 300 mg, qd, until disease progression or unacceptable toxicity. Tumor responses were assessed using RECIST v 1.1.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Jian Ming Xu
Keywords: sulfatinib, net, orr, pfs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p<0.0001).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Jie Li
Authors: Li J, Xu J, Zhou Z, Bai C, ...
#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Heying Duan
Authors: Duan H, Ninatti G, Girod B, Ferri V, ...
Keywords: NET, PRRT, ORR, PFS
#1444 Clinical Characteristic and Treatment Options of Patients with G3 Gastroenteropancreatic Neuroendocrine Neoplasms in China
Introduction: Well differentiated neuroendocrine tumor G3 (NET G3) patients are a special part of neuroendocrine neoplasms with a different biological behavior comparing with other G3 patients.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Ru Jia
Authors: Jia R, Tan H, Bai C M, Zhang P, ...
Keywords: NET G3, NEC, TEMCAP
#2143 Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams
Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Ru Jia
Authors: Jia R, Li Y L, Jin Y S, Chen Y, ...
#993 Analysis of Somatostatin Receptors Expression in Neuroendocrine Tumors
Introduction: Clinical studies have suggested anti-tumor efficacy of somatostatin analog (SSA) in the treatment of neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Tingting Li
Authors: Li T, Qian Z, Ter-Minassian M, Chan J A, ...
Keywords: SSTR2, SSA, NET, OS, PFS